● pepmg Research Desk · Peer-reviewed evidence review
What the research says about follistatin
A neutral summary of the peer-reviewed literature on follistatin, an activin- and myostatin-binding protein studied in animal models of muscle growth and, in humans, mostly as a circulating metabolic biomarker. No controlled human administration trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Follistatin is a glycoprotein that binds and neutralizes activin and myostatin, both members of the TGF-beta superfamily; because myostatin restrains muscle growth, blocking it is the basis of follistatin's muscle-building reputation [1][2].
- In animal models, follistatin and follistatin-derived peptides increase skeletal muscle mass through the IGF-1 receptor/Akt/mTOR pathway and via myostatin inhibition [2][4].
- Human follistatin studies in this corpus mostly measure naturally circulating follistatin as a metabolic or reproductive biomarker, not injected follistatin; there are no controlled human trials of follistatin administration for muscle here, and an anti-doping study found many black-market "follistatin" products did not even contain follistatin [6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What follistatin is
Follistatin was first described as a substance in ovarian follicular fluid that inhibited follicle-stimulating hormone, but it is now understood as a broadly acting regulatory protein. Its defining biochemical property is a high affinity for activin: by binding activin, follistatin neutralizes activin's effects, and this activin-follistatin interplay regulates many cellular processes across reproductive and non-reproductive tissues [1]. Follistatin also binds and inhibits myostatin, another TGF-beta superfamily ligand [2][4].
Myostatin is a negative regulator of muscle growth, so a myostatin-binding protein like follistatin is an attractive experimental tool for muscle-wasting conditions and the reason follistatin is marketed for physique goals [4]. It is sold in forms labeled "follistatin 344" (FS344) and "follistatin 315" [6]. Follistatin has never been an approved medicine; material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the research has measured
Preclinical onlyThe muscle-growth evidence is preclinical. In animal work, follistatin is described as inducing a dramatic increase in skeletal muscle mass that requires the type-1 IGF-I receptor/Akt/mTOR pathway, and it retained its hypertrophic effect even when circulating IGF-I was very low [2]. Investigators have also engineered follistatin-derived fragments: a study identified a short myostatin-inhibitory peptide from follistatin's N-terminal domain that, injected intramuscularly, increased muscle in an animal model while sparing activin and TGF-beta1 inhibition [4]. Another animal study delivered recombinant follistatin protein to reinnervated muscle in rats to test whether it enhances muscle recovery after nerve repair [5].
Human follistatin studies in this corpus are largely about the protein the body makes itself, not about administering follistatin. Reviews describe circulating follistatin as substantially liver-derived and regulated by the glucagon-to-insulin ratio, linking it to energy metabolism [3], and summarize associations between follistatin (and the related FSTL3) and metabolic disorders such as type 2 diabetes and obesity, while noting the outcomes are contradictory and do not support firm conclusions [7]. Follistatin has also been examined as a monitoring or prognostic biomarker in muscular dystrophy [8]. These are observational and mechanistic studies of endogenous follistatin, not trials of the product sold to build muscle.
Put plainly: the striking muscle-mass effects are from animals and gene- or protein-delivery experiments, and the human data measure naturally occurring follistatin. No controlled human trial in this corpus tests whether administering follistatin produces muscle growth or any clinical benefit in people.
What the studies report on safety and adverse events
Preclinical onlyBecause there are no controlled human administration trials of follistatin in this corpus, there is no controlled human safety or adverse-event data to report. The animal muscle studies focus on efficacy endpoints such as muscle mass rather than systematic safety characterization, and follistatin's broad activity across the activin/TGF-beta system, which governs many tissues beyond muscle, is a reason that off-target effects would need careful study before any human conclusions.
A product-integrity finding is directly relevant to anyone considering material sold as follistatin. An anti-doping analysis of black-market products, where follistatin is a prohibited substance and no approved pharmaceutical formulation exists, found that only nine of the seventeen tested products actually contained follistatin, and that some of the others instead contained different growth-promoting peptides [6]. This is a concrete illustration that a vial labeled follistatin may not contain what the label claims.
None of this is a safety guarantee. Follistatin is an experimental protein with no controlled human evaluation here, and research-chemical material is not manufactured to pharmacy standards or verified for identity, as the black-market analysis shows. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as preclinical for the muscle-growth uses follistatin is marketed around. Those effects are documented in animal models and protein/gene-delivery experiments [2][4][5], not in controlled human administration trials, which are absent from this corpus. The human follistatin literature is real but answers a different question: it characterizes endogenous circulating follistatin as a metabolic and reproductive biomarker, with some findings described by their own authors as contradictory [3][7][8].
"Preclinical" is therefore the honest ceiling for the physique claims, and the black-market product-identity finding [6] is an added reason for caution. Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- Follistatin: a multifunctional regulatory protein.
- Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.
- Circulating follistatin in relation to energy metabolism.
- Discovery of a follistatin-derived myostatin inhibitory peptide.
- Follistatin Protein Enhances Satellite Cell Counts in Reinnervated Muscle.
- Detection of black market follistatin 344.
- Follistatin and follistatin-like 3 in metabolic disorders.
- Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.